Troutman Pepper client Apnimed, Inc., a clinical-stage pharmaceutical company focused on developing oral pharmacologic therapies for the treatment of obstructive sleep apnea (OSA) and other sleep disorders, announced a new joint venture with Shionogi & Co., Ltd., a leading global research-driven pharmaceutical company based in Japan, to develop novel pharmacologic therapies to treat OSA and other sleep disorders. Shionogi also made an equity investment in Apnimed.
Apnimed is a clinical-stage pharmaceutical company working to transform the treatment of sleep apnea based on a simple idea – patients with obstructive sleep apnea could benefit from treatment with a safe and effective oral medication dosed once daily at bedtime. Apnimed’s lead development program targets the neurologic control of upper airway muscles to maintain an open airway during sleep.
The newly formed joint venture, Shionogi-Apnimed Sleep Science, LLC, initially focuses on accelerating the discovery, preclinical and clinical development of novel pharmacologic solutions designed to address the complex pathology of OSA. Shionogi-Apnimed Sleep Science combines Apnimed’s knowledge of OSA, highly experienced clinical-stage drug development team and robust network of sleep medicine clinical sites with Shionogi’s highly efficient small molecule drug discovery engine and proven ability to create best-in-class compounds.
The Troutman Pepper team advising Apnimed includes Dan Sieck, Chris Miller, Judith O’Grady, Saba Ashraf, and Joe Goldman. Apnimed has been a member of Troutman Pepper’s Startup and Early-Stage Entrepreneurial Development (SEED) Program since the company’s inception. The program combines the resources of an experienced, multidisciplinary team into an affordable package for startups, early-stage, and fast-growing companies. Clients receive legal counsel, mentoring, relationship-building opportunities, and more.
The firm regularly advises startup, emerging growth and venture capital clients through every stage of their life cycle. Industries served span software, hardware and other high-technology, biotechnology, pharmaceuticals and medical devices, financial technology, health care, consumer products, food and beverage, media and telecommunications products and services, and many others.
Original source can be found here.